ABSTRACT
INTRODUCTION
Topical anti-allergy agents and steroids are the firstline treatments for severe allergic conjunctivitis, such as vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC). However, these diseases require long-term treatment in many cases, and steroids cannot be administered because long-term steroid therapy often results in significant adverse reactions such as increased intraocular pressure, 1 especially in children under the age of 10 years, 2 as well as infections. 3 It is also true, however, that there are few effective treatment options for severe allergic conjunctivitis that provide as an alternative to topical steroids. 4 Tacrolimus is a macrolide antibiotic produced by Streptomyces tsukubaensis. 5 Due to its potent immunosuppressive effect, oral and parenteral tacrolimus preparations were developed for preventing rejection after organ transplantation. Subsequently, tacrolimus ointment was released for atopic dermatitis and autoimmune skin diseases, and it is now available all over the world. In recent years, there have been several reports about the usefulness of cyclosporin ophthalmic solution and tacrolimus ointment for the treatment of VKC and AKC. [6] [7] [8] [9] [10] Both of these drugs are calcineurin inhibitors that block the activation of T cells and their production of cytokines involved in the development of VKC and AKC. Based on the fact that the inhibitory effect of tacrolimus on cytokine production by T cells is about 100 times greater than that of cyclosporin, 11 an ophthalmic tacrolimus preparation is expected to be effective for severe VKC and AKC. Previously, we examined the efficacy of a 0.1% tacrolimus ophthalmic suspension (TALYMUS ® , Senju Pharmaceutical Co., Ltd., Osaka, Japan) for severe allergic conjunctivitis in a multicenter, randomized, double-blinded, placebo-controlled clinical trial. 12 Fifty-six patients were treated either with tacrolimus or placebo twice daily for 4 weeks. As a result, both objective findings and subjective symptoms were significantly better in the tacrolimus group than in the placebo group.
Although tacrolimus is a very useful immunosuppressant, it is known from previous experience with oral preparations that a persistently high blood concentration of the drug (trough level " 10-20 ng! mL) is associated with renal impairment. 13 On the other hand, after topical application of tacrolimus ointment for treatment of atopic dermatitis, the blood concentration is usually low or undetectable. 14 However, Rita L et al. recently reported that there may be an increased risk of T cell lymphoma in atopic dermatitis patients treated with tacrolimus ointment. 15 The theoretical risk of cancer from exposure is low because no evidence of systemic accumulation has been observed after repeated application of tacrolimus ointment. However, younger patients with a higher body surface area per weight and subjects with abnormalities of the epidermis can display considerable percutaneous absorption of tacrolimus ointment that may result in blood concentrations corresponding to the levels known to cause immunosuppression. The risk of severe systemic reactions to tacrolimus may depend on its blood level. Therefore, this study was conducted to clarify the blood level of tacrolimus after ocular instillation of a 0.1% ophthalmic suspension in patients with severe allergic conjunctivitis and to examine adverse drug reactions.
METHODS
This multicentre, prospective, open-label, non-comparative clinical study of patients with severe allergic conjunctivitis (VKC and AKC) was conducted at 11 institutions. We diagnosed VKC patients for characteristic appearances such as giant papillae in upper tarsal conjunctivae, Trantas dot in limbal conjunctivae. A various corneal disorders such as superficial punctate keratitis, shield ulcer and corneal plaque were observed in corneas of VKC patients. 15 VKC patients were enrolled in this study. On the other hand, chronic AKC patients had fibrosis of upper tarsal conjunctivae and neovascularization of corneas. However, acute AKC patients had severe papillae in upper tarsal conjunctivae and various corneal disorders. In this study, among AKC patients, we chose patients with severe papillae in upper tarsal conjunctivae. 37 AKC patients were enrolled in this study. The study was performed from May 2008 to September 2009 and its protocol was approved by the Institutional Review Boards of all participating institutions. In addition, the study was carried out in accordance with the Declaration of Helsinki, Good Clinical Practice, and Good Post-marketing Study Practice (Japan). All patients who participated in this study gave written consent after the details had been explained to them. The study was registered with the Japanese University Hospital Medical Information Network (https:! ! center.umin.ac.jp) and was assigned the ID code UMIN000001262.
Patients who had been diagnosed as having severe allergic conjunctivitis and for whom topical antiallergic agents were ineffective were eligible for this study. The following patients were excluded from the study: (1) those who had known hypersensitivity to tacrolimus hydrate or to any component of this drug; (2) those with infectious eye diseases; (3) women who were pregnant or possibly pregnant; (4) patients who had already used an ophthalmic preparation of tacrolimus hydrate (including in clinical trials); (5) patients using tacrolimus capsules, granules and! or injections; (6) patients who wore contact lenses; and (7) patients who had participated in any other clinical trial within 3 months prior to enrollment.
Patients were instructed to instill one drop of 0.1% tacrolimus ophthalmic suspension into both eyes twice a day for 12 weeks. Patient's compliances with the administration of the drug were confirmed at each observational time point during the study. Almost patients were in compliance with the rule of prescriptions in this study. Concomitant administration of tacrolimus ointment for severe atopic dermatitis was allowed without any dose change from 4 weeks prior to and during the study. Safety was assessed from ocular findings, visual acuity, intraocular pressure, adverse events, and laboratory test results. All adverse events observed by the investigators or reported by patients in weeks 2, 4, 8, and 12 were recorded. Each event was graded as mild, moderate, or severe, and the potential relationship to the study drug was assessed. For laboratory tests, blood samples were obtained from a cubital vein in weeks 4 and 12.
To evaluate systemic absorption after topical instillation of 0.1% tacrolimus ophthalmic suspension, approximately 1 mL of whole venous blood was collected before the initiation of administration and after 4 and 12 weeks of treatment. We collected blood samples at three-four hours after the last administration of tacrolimus suspension. The blood concentration of tacrolimus was measured by using liquid chromatography tandem mass spectrometry (LC-MS 2 ) at the Osaka laboratory of JCL Bioassay Corp. (Osaka, Japan). LC-MS 2 is widely used for quantitative determination of immunosuppressive drugs in biological fluids, because of the features such as selectivity and lower cost of analysis. 16 Ten ocular findings were assessed, including 5 for the tarsal conjunctiva (hyperemia, swelling, follicles, papillae, and giant papillae), 2 for the bulbar conjunctiva (hyperemia and edema), and limbal edema, Trantas' dots, and corneal lesions. Six ocular symptoms were also assessed, including itching, eye discharge, lacrimation, eye pain, foreign body sensation, and photophobia. Each of these signs! symptoms was graded on a 4-point scale (0 = none, 1 = mild, 2 = moderate, or 3 = severe). The primary efficacy outcome measure was the mean change of the total score for the 10 ocular findings.
Statistical analysis was performed using JMP statistical software (version 8 for Windows, SAS Institute Inc., Cary, NC, USA). Significance was accepted at a two-sided level of P < 0.05. Efficacy assessments were based on the worse eye (the eye with a higher total score for ocular findings), with the total scores being compared between baseline and post-treatment by the Wilcoxon signed rank test.
RESULTS

PATIENT PROFILE
The baseline characteristics and clinical scores of the subjects are shown in Table 1 . A total of 52 patients (42 males and 10 females) were enrolled. The mean age was 17.4 years for those with AKC and 14.1 years for those with VKC. In 18 of the 37 AKC patients and 6 of the 15 VKC patients, corticosteroid eye drops and! or ointment were being used at study initiation. However, only 5 patients with AKC were still using steroids at the completion of the study. Tacrolimus ointment was used by 7 patients for treatment of severe atopic dermatitis. Table 2A , B show the blood levels of tacrolimus in various subsets of patients without or with concomitant using of tacrolimus ointment at all the three points (Initial! week4 and week12). About 75% of the patients without concomitant using of tacrolimus ointment had blood levels below the detection limit of the assay (0.5 ng! mL). In the other hand, 71% (week 4) and 57% (week12) of patients with concomitant using of tacrolimus ointment had blood levels above the detection limit of the assay (0.5 ng! ml). However, the maximum blood concentrations of both groups were always less than 2 ng! mL. In the others, the mean blood level was not affected by sex, age, steroid ther- 
BLOOD LEVEL OF TACROLIMUS
SAFETY
Adverse drug reactions were reported in 16 patients. The incidence of adverse drug reactions among the 20 patients who had detectable blood levels of tacrolimus was 30.0%, which was very close to the 31.3% for patients without detectable levels (below the lower limit of quantification). All of the adverse drug reactions are listed in Table 3 . No serious adverse events or ocular infections occurred during the treatment with the study drug. Although laboratory abnormalities occurred in 8 cases, no clinically relevant problems were observed.
The changes from baseline of visual acuity and intraocular pressure after 12 weeks are shown in Table  4 . Baseline of visual acuities of patients was improved. As for the mean intraocular pressure, elevation was not recognized in patients with or without concomitant steroid use.
EFFICACY
At the start of treatment, the mean symptom score was 7.7 ± 4.46 in the steroid group and 5.5 ± 3.54 in the non-steroid group. These scores showed a significant decrease to 2.5 ± 3.01 (P < 0.001) and 2.0 ± 2.04 (P < 0.001), respectively, in week 2 (Fig. 1) . The scores decreased further to 1.2 ± 1.93 for the steroid group and 0.9 ± 1.42 for the non-steroid group by week 12. As for ocular findings, the mean score at the start of treatment was 16.0 ± 5.26 for the steroid group and 15.8 ± 4.42 for the non-steroid group. These scores decreased significantly to 10.8 ± 4.66 (P < 0.001) and 9.9 ± 3.36 (P < 0.001), respectively, in 
No. of detected / total patients. *P value were calculated with the use of MANOVA test. week 2, and then decreased further to 6.5 ± 3.44 and 4.5 ± 3.15, respectively, by week 12.
DISCUSSION
The 0.1% ophthalmic suspension of tacrolimus is a topical preparation of calcineurin inhibitor that was developed specifically for the treatment of severe allergic conjunctivitis, including VKC and AKC. Tacrolimus inhibits calcineurin activity, leading to marked suppression of the production of various cytokines by activated T cells (including IL-2, IL-4, IL-5, and interferon-gamma). 17 On account of its potent immunosuppressive activity, tacrolimus was considered to show promise for application to intractable allergic eye diseases. After studies conducted in Japan proved the usefulness of 0.1% tacrolimus ophthalmic suspension, 12 it was released in 2008.
On the other hand, it is known that adverse drug reactions to tacrolimus, such as renal dysfunction, tend to occur with systemic use when a whole blood concentration of about 10 ng! mL (trough level) persists for a long time. 13 Furthermore, a recent review focused on the potential risk of T cell lymphoma in patients using tacrolimus ointment. 15 The age-and sex-adjusted hazard ratio for T cell lymphoma was 5.44 (95% Cl: 2.51-11.79; P < 0.001) for patients exposed to tacrolimus versus those not exposed. However, no data on the blood levels of tacrolimus were reported for the patients who developed T cell lymphoma. Because systemic immunosuppression is associated with an increased risk of lymphoma, there is a theoretical possibility that tacrolimus ointment could increase the risk of lymphoma. However, there is no evidence of a causal link between cancer and tacrolimus. [18] [19] [20] [21] [22] [23] [24] [25] Many pharmacokinetic studies have shown that systemic exposure to tacrolimus is low in patients using the ointment, with blood concentrations being below the limit of quantification (0.5 ng! mL) in the majority of patients. [26] [27] [28] [29] [30] [31] In this study, to evaluate the safety of 0.1% tacrolimus ophthalmic suspension, we investigated the blood level of tacrolimus in patients using the suspension. Blood levels of tacrolimus were monitored in all 52 patients during the study period. About 75% of the patients without concomitant using tacrolimus ointment had blood levels below the detection limit of the assay (0.5 ng! mL). On the other hand, 71% (week 4) and 57% (week 12) of patients with concomitant using of tacrolimus ointment had blood levels above the detection limit of the assay (0.5 ng! ml). However, the maximum blood concentration was lower than 2 ng! mL, which was less than high risk level (10 ng! mL) at which systemic adverse drug reactions might occur. Therefore, the theoretical risk of adverse effects Fig. 1 Changes of the total scores for symptoms and signs during the 12-week study period. Error bars represent the standard deviation. The signifi cance of differences was evaluated by using the Wilcoxon signed rank test to assess the change of each score in comparison with the baseline value. *P < 0.0001. due to exposure to tacrolimus is very low because no evidence of accumulation was observed after repeated use of 0.1% tacrolimus ophthalmic suspension with or without concomitant using of tacrolimus ointment. Despite this finding, especially for patients with concomitant using of tacrolimus ointment, caution may be required to monitor the blood level of tacrolimus. Among the 52 patients, adverse drug reactions occurred in 16. The most common adverse events associated with 0.1% tacrolimus ophthalmic suspension treatment were transient application-site reactions, such as warmness, irritation, and a burning sensation. However, all of the patients could continue treatment with tacrolimus for 12 weeks. These complications were related to their ocular diseases and decreased in frequency over time as allergic conjunctivitis showed improvement. Because tacrolimus modulates the local immune response at the ocular surface, treatment with 0.1% tacrolimus ophthalmic suspension could theoretically increase the risk of infections. However, there was no increase in the incidence of infections among adults or children in the present study. Despite this finding, especially for patients with a history of herpes simplex infection, caution may be required to prevent recurrence during long-term treatment. 32 During this study, when 0.1% tacrolimus ophthalmic suspension was used for 12 weeks, giant papillae and corneal disorders showed marked improvement. The effect was significant after only 2 weeks of treatment, and both symptoms and objective findings responded quickly to 0.1% tacrolimus ophthalmic suspension.
In conclusion, we evaluated the safety and efficacy of 0.1% tacrolimus ophthalmic suspension in patients with severe allergic conjunctivitis. On the basis of the blood concentration profile of tacrolimus, systemic exposure was minimal and transient after topical application of the ocular preparation. The safety of 0.1% tacrolimus ophthalmic suspension and its demonstrated efficacy make it an important option for the treatment of severe allergic conjunctivitis.
